Mahamaya Lifesciences Ltd (MAHALIFE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Mahamaya Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
Submission of Non-Applicability of Compliance of Corporate Governance as required under Regulation 27(2) of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 29 Oct 2026, 10:03 pm
Mahamaya Lifesciences Confirms Corporate Governance Non-Applicability for Q2 FY27 Mahamaya Lifesciences Limited announced the non-applicability of corporate governance reporting requirements under Regulation 27(2) of SEBI LODR Regulations for the quarter ended 30th Sep'26. As an entity listed on the BSE SME platform, the company is exempt under Regulation 15(2)(b) from filing quarterly corporate governance compliance reports. Practicing Company Secretaries firm HPN & Associates issued a formal certification verifying the statutory exemption for the period.
Publication of Executive Interview in AgroPages Magazine (2026 India Focus Issue)
Others (Uncategorized) · 09 Oct 2026, 11:15 pm
Mahamaya Lifesciences Outlines Strategic Growth, Financial Expansion, and Dahej Facility Roadmap Mahamaya Lifesciences reported robust FY'25–'26 performance, with revenue up 24.5% YoY to Rs. 328.87 crore, EBITDA rising 32.6% YoY to Rs. 34.26 crore, and PAT surging 29.0% YoY to Rs. 16.52 crore. Net debt-to-equity improved to 0.74x from 1.18x. The company is deploying IPO proceeds toward backward integration at Dahej, Gujarat, targeting formulation expansion and pilot operations by Dec'26, followed by commercial technical production in 2027. Strategic focus includes expanding proprietary branded products, high-margin bio-fermented solutions, and overseas registrations across LatAm, Middle East, and Africa.
Appointment of Dr. Bhagirath Choudhary as Independent Director, Re-appointment of Dr. Charudatta Digambar Mayee as Independent Director, Re-appointment of Mr. Gopal Krishna Raju as Independent ....
Change in Management · 30 Sept 2026, 4:45 pm
Mahamaya Lifesciences Limited has informed the exchange regarding the voting results and scrutinizer report of the 24th Annual General Meeting held on September 29, 2026
Annual General Meeting · 30 Sept 2026, 4:34 pm
Mahamaya Lifesciences Limited has informed the exchange regarding proceedings of 24th Annual General Meeting held on September 29, 2026
Annual General Meeting · 29 Sept 2026, 6:46 pm
Annual Report for the Financial Year 2025-26
Others (Uncategorized) · 08 Sept 2026, 2:38 am
Notice of 24th Annual General Meeting scheduled to be held on Tuesday, September 29, 2026
Annual General Meeting · 08 Sept 2026, 2:03 am
Appointment of Mr. Bhagirath Choudhary as Additional Independent Director, Re-appointment of Dr. Gopal Krishna Raju as Independent Director, Re-appointment of Dr. Charudatta Digambar Mayee ....
Change in Management · 25 Aug 2026, 7:13 pm
Mahamaya Lifesciences Announces Major Leadership Reshuffle and Key Appointments Effective 01 Nov'26, Prashant Krishnamurthy will be promoted from Executive Director to Managing Director, while resigning as CFO on 31 Oct'26. Amarendra Mohapatra will become the new CFO. Krishnamurthy Ganesan will transition from MD to Chairman and Executive Director. The board also approved reappointing two Independent Directors and appointing one new Independent Director. Additionally, Kush Mishra has been appointed as Company Secretary from 25 Aug'26, and remuneration for key personnel will be revised from 01 Nov'26, pending shareholder approval.
Relinquishment from the post of Mr. Prashant Krishnamurthy as Chief Financial Officer upon the closure of business hours on October 31, 2026 and Appointment of Mr. Amarendra Mohaptra as ....
Change in Management · 25 Aug 2026, 7:08 pm
Mahamaya Lifesciences Announces Major Leadership Reshuffle and New CFO Mahamaya Lifesciences announced a significant leadership transition from its board meeting on Aug 25, '26. Prashant Krishnamurthy will resign as CFO on Oct 31, '26, and be re-designated as Managing Director from Nov 01, '26. He will be succeeded as CFO by Amarendra Mohapatra. Concurrently, Krishnamurthy Ganesan will transition from Managing Director to Chairman & Executive Non-Independent Director. The board also re-appointed two Independent Directors and appointed a new Company Secretary, Kush Mishra, effective Aug 25, '26.
Appointment of Mr. Kush Mishra as Company Secretary and Compliance Officer
Change in Management · 25 Aug 2026, 7:00 pm
Mahamaya Lifesciences Announces Key Leadership Changes and Board Appointments The Board of Mahamaya Lifesciences, on Aug 25, '26, announced significant leadership changes effective Nov 01, '26. Prashant Krishnamurthy will resign as CFO and be re-designated as Managing Director. Krishnamurthy Ganesan will relinquish his MD role to become Chairman and Executive Non-Independent Director. Amarendra Mohapatra will be elevated to the CFO position. Additionally, Kush Mishra was appointed Company Secretary effective Aug 25, '26. The Board also approved the appointments of a new Additional Director, Mr. Bhagirath Choudhary, and re-appointed two Independent Directors.
Investor Presentation to be shared during Investor Meet scheduled to be held on 07th August, 2026
Investor Presentation · 07 Aug 2026, 5:18 pm
Mahamaya Lifesciences to Hold Investor Meet on 7th Aug'26 Mahamaya Lifesciences (BSE: 544611) announced it will share an Investor Presentation during its Investor Meet scheduled for 07 Aug'26, starting at 4:00 PM IST. The company has made the presentation available on its website for information dissemination. Management has stated that the presentation does not contain any unpublished price-sensitive information.
Intimation of Schedule of Analyst(s) /Investor(s) meeting
Intimation · 04 Aug 2026, 10:45 pm
Mahamaya Lifesciences Schedules Investor & Analyst Call for 7th August Mahamaya Lifesciences (BSE: 544611) will host a virtual investor and analyst group meeting on 07th Aug'26, starting at 4:00 PM IST. Management, including MD Krishnamurthy Ganesan and ED & CFO Prashant Krishnamurthy, will participate. Discussions will be based on publicly available information, with no unpublished price-sensitive details to be shared. The company noted the meeting could be cancelled or rescheduled.
Resignation of Company Secretary and Compliance Officer
Change in Management · 30 Jul 2026, 11:34 pm
Mahamaya Lifesciences Announces Resignation of Company Secretary and KMP Ms. Shilpi Bhardwaj has resigned as Company Secretary, Compliance Officer, and Key Managerial Personnel of Mahamaya Lifesciences Limited to pursue other career opportunities. She tendered her resignation on 10th Jun'26, and her last day will be the close of business on 30th Jul'26. The company confirmed there are no other material reasons for her departure. This senior management change is a key event under SEBI's Regulation 30 disclosure requirements, necessitating the search for a replacement for these critical compliance roles.
Submission of Non-applicability of the Compliance on Corporate Governance as required under Regulation 27(2) of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 10 Jul 2026, 11:34 pm
Mahamaya Lifesciences Exempt from Q1FY27 Corporate Governance Reporting Mahamaya Lifesciences Limited has notified BSE that it is not required to submit the Corporate Governance Report for the quarter ended 30 Jun'26. This exemption is per SEBI (LODR) Regulation 15(2)(b), which applies to companies listed on the SME Platform. As an SME-listed entity, the provisions under Regulation 27(2) regarding corporate governance compliance do not apply. The company submitted a certificate from HPN & Associates, Company Secretaries, confirming the non-applicability, dated 10 Jul'26.
Submission of Press Release on Audited Financial Results for FY26
Press Release · 26 May 2026, 6:43 pm
Mahamaya Lifesciences Reports Strong FY26 with 25% YoY Revenue Growth Mahamaya Lifesciences reported strong FY26 results with revenue from operations growing 24.5% YoY to ₹32,887.30 lakhs. EBITDA increased 32.06% YoY to ₹3,425.88 lakhs, with the EBITDA margin expanding by 60 bps to 10.42%. Profit After Tax (PAT) rose 28.97% YoY to ₹1,652.33 lakhs, despite being impacted by ₹411 lakhs in forex losses and listing expenses. Diluted EPS for FY26 stood at ₹8.33, up 10.77% YoY. For H2 FY26, revenue was ₹16,580.93 lakhs with an EBITDA of ₹1,789.84 lakhs.
Audited Financial Results (Standalone & Consolidated) of the Company for the half year and financial year ended 31.03.2026, along with the Audit Reports thereon.
Financial Result · 25 May 2026, 7:25 pm
Mahamaya Lifesciences FY26 Results: Strong Revenue and Profit Growth YoY Mahamaya Lifesciences reported consolidated net profit of ₹1,652.33 lakhs for FY26, up 29.0% YoY from ₹1,281.16 lakhs. Revenue from operations grew 24.5% YoY to ₹32,887.30 lakhs. For H2FY26, revenue stood at ₹16,580.93 lakhs and net profit was ₹815.46 lakhs. The board approved the audited standalone and consolidated financial results for the half-year and full-year ended 31st Mar'26. Basic consolidated EPS for FY26 was ₹8.33 versus ₹7.52 in FY25. The statutory auditors issued an unmodified opinion.
Audited Financial Results along with Auditors Report for the half year and financial Year ended on 31st March, 2026
Outcome · 25 May 2026, 7:09 pm
Mahamaya Lifesciences Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 16,581 (+0.0% YoY | +1.7% QoQ) ■ EBITDA: 1,738 (+0.0% YoY | +12.7% QoQ) ■ EBITDA Margin (%): 10.5 (+0 bps YoY | +103 bps QoQ) ■ PAT: 815 (+0.0% YoY | -2.6% QoQ) ■ EPS (INR): 3.72 (+0.0% YoY | -21.0% QoQ)
Mahamaya Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve We wish to inform you ....
Intimation · 25 May 2026, 5:30 am
Mahamaya Lifesciences Board Meeting to Approve FY26 Financial Results Mahamaya Lifesciences has scheduled a board meeting for 25th May'26 to consider and approve its audited standalone and consolidated financial results for the half-year and full-year ended 31st Mar'26. In accordance with regulations, the trading window for insiders will remain closed until 48 hours after the declaration of the financial results.
Submission of Monitoring Agency Report for the half year ended on March 31, 2026
Others (Uncategorized) · 15 May 2026, 7:02 pm
Mahamaya Lifesciences Delays Capex, Extends IPO Fund Utilization Timeline to FY28 Mahamaya Lifesciences has utilized ₹29.17 crore (47%) of its ₹61.96 crore net IPO proceeds as of 31 Mar'26, with ₹32.79 crore remaining. In its first monitoring report covering 18 Nov'25 to 31 Mar'26, the company confirmed no deviation from stated objectives. However, on 10 Mar'26, the Board approved rescheduling the utilization of unspent funds, extending the timeline up to 31 Mar'28. This delay is attributed to extended project execution timelines for establishing a new technical manufacturing plant, a key objective for backward integration.
Announcement under Regulation 30 (LODR)-Receiving a Certificate of Appreciation from Business Connect under the Category "Quality Excellence Award-Adherence to Global Quality Standards (GMP)"
Others (Uncategorized) · 04 May 2026, 9:52 pm
Mahamaya Lifesciences Receives Quality Excellence Award for GMP Adherence Mahamaya Lifesciences (BSE: 544611) announced on 04 May '26 it has received a Certificate of Appreciation from Business Connect. The recognition falls under the "Quality Excellence Award – Adherence to Global Quality Standards (GMP)" category. This award acknowledges the company's commitment to maintaining high-quality manufacturing practices, a key factor for operational integrity and market trust in the lifesciences sector. The intimation was made under Regulation 30 of SEBI (LODR) regulations.
Pursuant to Regulation 30 of SEBI (LODR), we pleased to announce that our company has been awarded as "Great Place to Work" certification.
Others (Uncategorized) · 28 Apr 2026, 9:07 pm
Mahamaya Lifesciences Awarded 'Great Place To Work' Certification Mahamaya Lifesciences Limited (BSE: 544611) announced on 28 Apr 2026 it has received the "Great Place to Work" certification in India under the 'Under 100 Employees' category. The certification, awarded by Great Place To Work® India, is valid from Apr '26 to Apr '27. This development was disclosed as per Regulation 30 of SEBI's LODR Regulations, highlighting a positive corporate culture milestone.
Submission of Non-Applicability of the Compliance on Corporate Governance as required under Regulation 27(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
Others (Uncategorized) · 15 Apr 2026, 11:35 pm
Mahamaya Lifesciences Exempt from SEBI Corporate Governance Reporting Mahamaya Lifesciences Limited informed BSE on 15 Apr'26 that it is exempt from filing Corporate Governance Reports under Regulation 27(2) of SEBI (LODR) Regulations, 2015. The company stated it fulfills the non-applicability criteria specified in Regulation 15(2)(b), as its equity shares are listed on the BSE SME Platform. Consequently, Mahamaya will not submit quarterly, half-yearly, or yearly Corporate Governance reports, which would otherwise be required.
Annual Disclosure under Regulation 31(4) of SEBI (SAST) Regulation, 2011, received from the Promoter and Promoter Group is enclosed.
Others (Uncategorized) · 03 Apr 2026, 9:34 pm
Mahamaya Lifesciences: Promoter Group Confirms No Share Encumbrance Mahamaya Lifesciences disclosed that its Promoter and Promoter Group, along with persons acting in concert, have created no encumbrances on their shareholdings for the financial year ended 31st Mar'26. This confirmation was submitted to the exchange on 3rd Apr'26, pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing indicates stability in the Promoter Group's equity stake, with no shares pledged or otherwise encumbered during the period.
We wish to inform you that the Board of Directors of the Company, through a circular resolution passed today, has approved the utilisation of the unutilized IPO proceeds in subsequent fiscal ....
Others (Uncategorized) · 10 Mar 2026, 6:51 pm
Mahamaya Lifesciences Extends IPO Fund Utilization Timeline to March 2028 Mahamaya Lifesciences' Board approved on 10th Mar'26 to extend the utilization timeline for its unutilized IPO proceeds to 31st Mar'28. The company raised Rs. 6,196.43 Lakhs from its Nov'25 IPO. As of 28th Feb'26, Rs. 2,747.40 Lakhs have been utilized, leaving an unutilized balance of Rs. 3,449.03 Lakhs. The company cited project execution complexities and a limited window since receiving funds as reasons for the phased deployment. There is no change in the objects of the issue as stated in the prospectus.
with reference to our earlier intimation submitted to the exchange dated 05/03/2026 regarding participation in Arihant Capital Bharat Connect Virtual Conference Rising Star 2026 organised ....
Others (Uncategorized) · 09 Mar 2026, 4:49 pm
Mahamaya Lifesciences Withdraws From Arihant Capital Investor Conference Mahamaya Lifesciences (BSE: 544611) has withdrawn its participation from the Arihant Capital Bharat Connect Virtual Conference Rising Star 2026, which was scheduled for 9-Mar-26. The company cited internal scheduling constraints and ongoing business priorities as reasons for the cancellation. This update reverses the company's prior confirmation of attendance filed on 5-Mar-26.